Charles River Laboratories International Inc. (NYSE: CRL), fresh from the collapse of a proposed, $1.6 billion merger with WuXi PharmaTech (Cayman) Inc. (NYSE: WX), plans to accelerate a $300 million stock buyback and took out a $750 million credit line.
The Wilmington, Massachusetts-based contract research organization said the repurchasing plan will see it buy back 6 million shares initially, with the final number to be determined based on a discounted price based on its daily volume-weighted average price during a a six-month-or-less period as determined by Morgan Stanley & Co. Inc., which is brokering the buyback.
Charles River Labs said it will pay for the buyback using cash on hand and “available liquidity,” which includes a new $750 million credit agreement. The new line consists of a $400 million term loan and a $350 million revolving credit facility.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company spiked the WuXi merger in late July after running into a buzz saw of opposition from several institutional backers, who believed the deal was too pricey and would give WuXi a disproportionately large stake in the combined companies.
The failed merger only added to Charles River Labs’ woes during the second quarter, when it posted a 57.6 percent decline in profits on a 5.2 percent top-line slide and cut its sales and earnings forecast for the rest of the year.
CRL shares were trading at $29.06 in early-morning activity, up about 0.6 percent.
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
